Lantheus (NASDAQ:LNTH) Releases Q2 Earnings Guidance

Lantheus (NASDAQ:LNTH) updated its second quarter earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $1.81-1.86 for the period, compared to the consensus estimate of $1.66. The company issued revenue guidance of $380-390 million, compared to the consensus revenue estimate of $356.88 million. Lantheus also updated its FY24 guidance to $7.00-7.20 EPS.

Analyst Ratings Changes

Several analysts have issued reports on the company. Truist Financial restated a buy rating and issued a $82.00 price objective (up previously from $80.00) on shares of Lantheus in a research note on Monday, February 26th. B. Riley upped their price objective on Lantheus from $95.00 to $99.00 and gave the company a buy rating in a research note on Thursday, April 18th. StockNews.com upgraded Lantheus from a hold rating to a buy rating in a research note on Saturday, January 13th. Finally, JMP Securities restated a market outperform rating and issued a $100.00 price objective on shares of Lantheus in a research note on Friday, February 23rd. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Lantheus currently has a consensus rating of Moderate Buy and a consensus target price of $104.71.

Lantheus Stock Performance

NASDAQ:LNTH opened at $74.60 on Thursday. The stock has a 50 day simple moving average of $62.22 and a 200 day simple moving average of $62.69. The stock has a market cap of $5.11 billion, a P/E ratio of 14.52 and a beta of 0.52. Lantheus has a 1-year low of $50.20 and a 1-year high of $100.85. The company has a current ratio of 5.80, a quick ratio of 5.45 and a debt-to-equity ratio of 0.69.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, topping the consensus estimate of $1.33 by $0.26. The firm had revenue of $354.00 million for the quarter, compared to analysts’ expectations of $350.44 million. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. Research analysts anticipate that Lantheus will post 5.96 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Mary Anne Heino sold 93,863 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the sale, the director now directly owns 251,643 shares in the company, valued at $16,434,804.33. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was acquired at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the purchase, the insider now directly owns 116,773,394 shares in the company, valued at $110,934,724.30. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mary Anne Heino sold 93,863 shares of the business’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the transaction, the director now directly owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The disclosure for this sale can be found here. Insiders sold 94,545 shares of company stock worth $6,169,936 in the last quarter. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.